OPC-67683 is primarily used in the treatment of tuberculosis (TB), particularly multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). It belongs to the class of nitroimidazole compounds and works by inhibiting the synthesis of mycolic acids, which are essential components of the bacterial cell wall in Mycobacterium tuberculosis. This mechanism of action makes it effective against both actively growing and dormant TB bacteria, addressing a critical challenge in TB treatment. OPC-67683 is often included in combination therapies to enhance efficacy and reduce the risk of resistance development. Its role in treating drug-resistant TB has made it a valuable component in global efforts to combat this infectious disease, especially in regions where TB strains are resistant to conventional treatments.